A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to That of Adalimumab in the Treatment of Biologic Naive Subjects With Moderately-to-Severely Active Crohn's Disease
Phase of Trial: Phase III
Latest Information Update: 29 Nov 2019
Price : $35 *
At a glance
- Drugs Ustekinumab (Primary) ; Ustekinumab (Primary) ; Adalimumab
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms SEAVUE
- Sponsors Janssen
- 03 Oct 2019 Planned End Date changed from 21 May 2021 to 15 Jun 2021.
- 16 Jul 2019 Planned End Date changed from 20 May 2021 to 21 May 2021.
- 13 Jun 2019 Planned End Date changed from 17 Feb 2021 to 20 May 2021.